PDM-631
PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders[1].
Product Specifications
CAS Number
2095312-08-4
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Neurological Disease
Smiles
FC(F)(F)OC(C=C1)=CC=C1C[C@@H](N2C3=C(C(N=C(N3)C)=O)C(C4CC4)=N2)C
Molecular Formula
C19H19F3N4O2
Molecular Weight
392.37
References & Citations
[1]Maehara S, et al. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631. Eur J Pharmacol. 2017 Sep 15;811:110-116.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDE2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
